MedTrace Logo

Pain Response to Cannabidiol in Opioid-induced Hyperalgesia, Acute Nociceptive Pain and Allodynia By Using a Model Mimicking Acute Pain in Healthy Adults

NCT04059978 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2020-10-19

No results posted yet for this study

Summary

Prospective, randomized, placebo-controlled, double-blinded, crossover study to investigate the effect of cannabidiol (CBD) on remifentanil-induced hyperalgesia in healthy volunteers in a well-established acute pain model. Participants are randomized according to the order of the two treatments (CBD + Remifentanil or Placebo + Remifentanil).

Conditions

  • Acute Nociceptive Pain
  • Hyperalgesia
  • Allodynia
  • Opioid-induced Hyperalgesia

Interventions

DRUG

CBD

1600mg cannabidiol, single oral dose (8 ml oily solution)

DRUG

Placebo

Placebo p.o, single oral dose (8 ml oily solution)

DRUG

Remifentanil

Remifentanil 0.1 µg/kg/min i.v. for 30 min

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Tobias Schneider, MD · Department of Anaesthesiology, University Hospital of Basel

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-26
Primary Completion
2020-10-15
Completion
2020-10-15

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04059978 on ClinicalTrials.gov